Drd3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Protein Name | Dopamine Receptor D3 |
| Gene Symbol | drd3 |
| UniProt ID | P35462 |
| Molecular Weight | ~95-130 kDa (glycosylated) |
| Subcellular Localization | Plasma membrane, dendrites, synapses |
| Protein Family | D2-like dopamine receptor family (GPCR) |
| Signal Transduction | Gi/o protein-coupled, inhibits adenylate cyclase |
The Dopamine Receptor D3 (DRD3) is a G protein-coupled receptor encoded by the DRD3 gene. It belongs to the D2-like family of dopamine receptors and is predominantly expressed in the limbic system, making it a key player in reward processing, emotional regulation, and motivational behavior. DRD3 has attracted significant interest in neurodegenerative and psychiatric research due to its involvement in Parkinson's disease, restless leg syndrome, and neuropsychiatric disorders.
DRD3 contains the classic seven transmembrane domain architecture typical of GPCRs:
The DRD3 receptor has higher affinity for dopamine than DRD2, allowing it to be activated at lower neurotransmitter concentrations.
DRD3 mediates the following physiological functions:
DRD3 expression is altered in Parkinson's disease, particularly in the striatum and limbic regions. Post-mortem studies show increased DRD3 binding in the nucleus accumbens of PD patients, which may contribute to non-motor symptoms including depression, anxiety, and impulse control disorders. DRD3 antagonists have been investigated for treating levodopa-induced dyskinesias.
DRD3 is strongly implicated in restless leg syndrome pathogenesis. Genetic studies have identified DRD3 variants associated with RLS susceptibility. The receptor's role in modulating dopaminergic tone in the basal ganglia contributes to the characteristic urge to move during rest.
While not a primary neurodegenerative disorder, DRD3 dysfunction contributes to psychotic symptoms. Antipsychotic drugs target DRD3 along with DRD2, and certain DRD3 variants are associated with treatment response.
| Drug Class | Examples | Mechanism | Status |
|---|---|---|---|
| DRD3 Agonists | Pramipexole, Rotigotine | Activate receptor for therapeutic effect | FDA approved for PD |
| DRD3 Antagonists | SB-277011A | Block receptor signaling | Preclinical/Research |
| Partial Agonists | Cariprazine | Balanced receptor activation | FDA approved for schizophrenia |
The study of Drd3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Sokoloff P, et al. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. PMID:1973550
[2] Levant B, et al. (1992). Distribution of dopamine D3 receptor in rat brain. Synapse. PMID:1282044
[3] Schwartz JC, et al. (1993). Dopamine D3 receptor and Parkinson's disease. European Neurology. PMID:8324224
[4] Kitzerow J, et al. (2000). DRD3 antagonists and dyskinesia. Movement Disorders. PMID:10788782
[5] Garzón M, et al. (2009). DRD3 gene variants and susceptibility to restless leg syndrome. Neurology. PMID:19369647